Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Activity of and resistance to moxifloxacin in Staphylococcus aureus.

Literature DB >> 12654680

Activity of and resistance to moxifloxacin in Staphylococcus aureus.

Dilek Ince¹, Xiamei Zhang, David C Hooper.

Abstract

Moxifloxacin has enhanced potency against Staphylococcus aureus, lower propensity to select for resistant mutants, and higher bactericidal activity against highly resistant strains than ciprofloxacin. Despite similar activity against purified S. aureus topoisomerase IV and DNA gyrase, it selects for topoisomerase IV mutants, making topoisomerase IV the preferred target in vivo.

Entities: Chemical Species

Mesh：

Substances：

Year: 2003 PMID： 12654680 PMCID： PMC152517 DOI： 10.1128/AAC.47.4.1410-1415.2003

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

33 in total

1. Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin.

Authors: C Bisognano; P E Vaudaux; D P Lew; E Y Ng; D C Hooper
Journal: Antimicrob Agents Chemother Date: 1997-05 Impact factor: 5.191

2. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.

Authors: Dilek Ince; Xiamei Zhang; L Christine Silver; David C Hooper
Journal: Antimicrob Agents Chemother Date: 2002-11 Impact factor: 5.191

3. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.

Authors: B Fournier; D C Hooper
Journal: Antimicrob Agents Chemother Date: 1998-01 Impact factor: 5.191

4. In vitro activity of BAY 12-8039, a new fluoroquinolone.

Authors: J M Woodcock; J M Andrews; F J Boswell; N P Brenwald; R Wise
Journal: Antimicrob Agents Chemother Date: 1997-01 Impact factor: 5.191

5. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.

Authors: A Bauernfeind
Journal: J Antimicrob Chemother Date: 1997-11 Impact factor: 5.790

6. Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae.

Authors: Serge Houssaye; Laurent Gutmann; Emmanuelle Varon
Journal: Antimicrob Agents Chemother Date: 2002-08 Impact factor: 5.191

7. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors: E Y Ng; M Trucksis; D C Hooper
Journal: Antimicrob Agents Chemother Date: 1996-08 Impact factor: 5.191

8. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus.

Authors: T Takenouchi; F Tabata; Y Iwata; H Hanzawa; M Sugawara; S Ohya
Journal: Antimicrob Agents Chemother Date: 1996-08 Impact factor: 5.191

9. Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome.

Authors: E Y Ng; M Trucksis; D C Hooper
Journal: Antimicrob Agents Chemother Date: 1994-06 Impact factor: 5.191

10. A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus.

Authors: M Trucksis; J S Wolfson; D C Hooper
Journal: J Bacteriol Date: 1991-09 Impact factor: 3.490

23 in total

Review 1. Antimicrobial resistance: the example of Staphylococcus aureus.

Authors: Franklin D Lowy
Journal: J Clin Invest Date: 2003-05 Impact factor: 14.808

2. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.

Authors: Sachin S Bhagwat; Lakshmi A Mundkur; Shrikant V Gupte; Mahesh V Patel; Habil F Khorakiwala
Journal: Antimicrob Agents Chemother Date: 2006-08-28 Impact factor: 5.191

3. Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.

Authors: Trudy H Grossman; Douglas J Bartels; Steve Mullin; Christian H Gross; Jonathan D Parsons; Yusheng Liao; Anne-Laure Grillot; Dean Stamos; Eric R Olson; Paul S Charifson; Nagraj Mani
Journal: Antimicrob Agents Chemother Date: 2006-11-20 Impact factor: 5.191

4. Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus.

Authors: Jeffrey J Campion; Patrick J McNamara; Martin E Evans
Journal: Antimicrob Agents Chemother Date: 2005-01 Impact factor: 5.191

5. DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases.

Authors: Jacob Strahilevitz; Que Chi Truong-Bolduc; David C Hooper
Journal: Antimicrob Agents Chemother Date: 2005-12 Impact factor: 5.191

6. De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells Formed against Antituberculosis Drugs In Vitro.

Authors: Jees Sebastian; Sharmada Swaminath; Rashmi Ravindran Nair; Kishor Jakkala; Atul Pradhan; Parthasarathi Ajitkumar
Journal: Antimicrob Agents Chemother Date: 2017-01-24 Impact factor: 5.191

7. In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.

Authors: Olivier Grossi; Jocelyne Caillon; Cedric Arvieux; Cedric Jacqueline; Denis Bugnon; Gilles Potel; Antoine Hamel
Journal: Antimicrob Agents Chemother Date: 2007-06-18 Impact factor: 5.191

8. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.

Authors: Wolfgang Haas; Chris M Pillar; Christine K Hesje; Christine M Sanfilippo; Timothy W Morris
Journal: J Antimicrob Chemother Date: 2010-04-30 Impact factor: 5.790

9. Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.

Authors: Patrick Grohs; Isabelle Podglajen; Laurent Gutmann
Journal: Antimicrob Agents Chemother Date: 2004-08 Impact factor: 5.191

Review 10. Moxifloxacin: a review of its use in the management of bacterial infections.

Authors: Gillian M Keating; Lesley J Scott
Journal: Drugs Date: 2004 Impact factor: 9.546